Compare RPGL & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RPGL | BCDA |
|---|---|---|
| Founded | 2015 | N/A |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.7M | 14.5M |
| IPO Year | 2025 | N/A |
| Metric | RPGL | BCDA |
|---|---|---|
| Price | $0.57 | $1.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 29.5M | 90.8K |
| Earning Date | 02-16-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $2,364,485.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $38.62 | ★ N/A |
| Revenue Growth | ★ 339.01 | N/A |
| 52 Week Low | $0.23 | $1.00 |
| 52 Week High | $5.19 | $3.20 |
| Indicator | RPGL | BCDA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 34.21 |
| Support Level | N/A | $1.16 |
| Resistance Level | N/A | $1.34 |
| Average True Range (ATR) | 0.00 | 0.09 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 0.00 | 5.33 |
Republic Power Group Ltd is a Singapore-based provider of customized software development, technology solutions, consulting, and technical support services. The company specializes in real-time monitoring, resource allocation, surveillance, and threat detection software, with capabilities in AI and IoT integration to provide services to corporate clients and government agencies.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).